Combining two drug therapies, statins and imatinib, may be more beneficial for pulmonary hypertension management than using either alone. The laboratory of Daria Orszulak-Michalak in Poland investigated co-administration of rosuvastatin or simvastatin with imatinib in rats with experimentally-induced pulmonary hypertension and found a benefit in reducing disease severity. Both…
November is Prematurity Awareness Month, and in light of World Prematurity Day celebrated yesterday, November 17, Nationwide Children’s Hospital shared with the pulmonary hypertension community the benefits of administering Sildenafil to premature newborn babies with pulmonary hypertension. Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor more popularly…
A new study highlighting a diagnostic test based on peripheral blood for idiopathic pulmonary fibrosis entitled “Familial and sporadic idiopathic pulmonary fibrosis: making the diagnosis from peripheral blood” was recently published in BMC Genomics by Eric B Meltzer at Vanderbilt University Medical Center. In this study, the…
New research presented at the American College of Rheumatology’s Annual Meeting in Boston claims that end-stage lung disease patients with diseases like Scleroderma should not be denied the opportunity of receiving a lung transplant because of extra-pulmonary factors and, consequently, short- and long-term survival concerns. The…
November 18th has been officially named chronic thromboembolic pulmonary hypertension (CTEPH) Awareness Day. This will be the first ever awareness day dedicated specifically to CTEPH. Chronic thromboembolic pulmonary hypertension is caused by chronic blood clots in the lungs that cause pressure in the pulmonary arteries and the right side…
Photo of Roseanne Huber from https://phadailybeat.blogspot.pt The Pulmonary Hypertension Association recently reached out to running enthusiast and pulmonary hypertension patient Roseanne Huber from Florida to share her insightful story of taking control of her condition. Huber was diagnosed with the life-threatening disease in 2006…
Although riociguat is indicated for treatment of pulmonary hypertension, Bayer HealthCare is looking to repurpose the drug to treat patients with diffuse cutaneous systemic sclerosis (dcSSc). Bayer initiated a randomized, double-blind, placebo-controlled phase 2 study using riociguat in patients with the…
Members of the Pulmonary Hypertension Association (PHA) accompanied PH patients from across the country yesterday to meet with Members of Congress. November is Pulmonary Hypertension Awareness Month, and to boost support for national efforts against this life threatening cardiopulmonary disease, they discussed the everyday plight…
The American Heart Association’s (AHA) journal Circulation has announced plans for a new thematic series on the recent advances in diagnosing and treating Pulmonary Hypertension (PH), in which an expert research team will present progress made in the research field for the disease. The topics in the series include patient…
In a recent review published in Circulation, the official Journal of the American Heart Association, Jonathan and Stuart Rich examined the current status of the epidemiology, prognosis, and update of the clinical classification for PH. In the review, the authors mainly focus on the diagnostic approach of suspected Pulmonary Hypertension…
Last week, in a bold move to call for support of a rare and debilitating pulmonary disease, the Pulmonary Hypertension Association was featured on the largest screen in the world — the NASDAQ Tower on Times Square, just after ringing the opening bell for the opening of the…
In a recent study entitled “Blood Flow Vortices along the Main Pulmonary Artery Measured with MR Imaging for Diagnosis of Pulmonary Hypertension” the authors report that phase-contrast magnetic resonance (MR) imaging is an accurate method for diagnosing pulmonary hypertension by estimating increased mean pulmonary arterial pressure. The study…
Get regular updates to your inbox.
